

**In the Claims:**

1-123. (canceled).

124. (Currently amended) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:33 shown in Figure 23 (SEQ ID NO:33);
- (b) ~~the amino acid sequence of the polypeptide shown in Figure 23 (SEQ ID NO:33), lacking its associated signal peptide;~~
- (c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 23 (SEQ ID NO:33);~~
- (d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 23 (SEQ ID NO:33), lacking its associated signal peptide; or~~
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209790;  
wherein, the nucleic acid encoding said polypeptide is amplified in squamous cell-type lung carcinomas or colon tumors.

125. (Currently amended) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:33 shown in Figure 23 (SEQ ID NO:33).

126-128. Canceled.

129. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209790.

130. (Currently amended) A chimeric polypeptide comprising a polypeptide according to Claim 124 ~~419~~ fused to a heterologous polypeptide.

131. (Previously presented) The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.